BioSpace News Archive

The American Pharmacists Association and APhA Foundation, joined 20 other organizations in support of the National Forum for Heart Disease & Stroke Prevention’s Value & Access Initiative by signing a Joint Policy Statement, including recommendations that will expand access to care options for patients nationwide, especially in underserved or otherwise vulnerable populations.

Centene Corporation announced that it has been notified of an unsolicited “mini-tender” offer by TRC Capital Investment Corporation to purchase up to 2,000,000 shares of Centene’s common stock at an offer price of $59.00 net per share in cash

Santen Pharmaceutical Co., Ltd. and Orbis International announced a partnership to develop a suite of digital training tools that will continue to help eye care professionals around the world build their skills.

Brickell Biotech, Inc., a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, announced the pricing of an underwritten public offering of 17,500,000 shares of common stock or common stock equivalents and investor warrants to purchase up to an aggregate of 17,500,000 shares of common stock.

Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced the pricing of its previously announced underwritten public offering of 6,600,000 shares of its common stock at a public offering price of $14.50 per share.

Leap Therapeutics, Inc., a biotechnology company focused on developing targeted and immuno-oncology therapeutics, announced that it has commenced an underwritten public offering of its common stock and, in lieu of common stock, Leap intends to offer and sell to certain investors pre-funded warrants to purchase shares of its common stock.

Adamas Pharmaceuticals, Inc., a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, announced the completion of its evaluation of ADS-5102 in multiple sclerosis patients with walking impairment.

Catalyst Biosciences, Inc. announced that it is offering shares of its common stock in an underwritten public offering.

Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., announced that BAUSCH + LOMB ULTRA® monthly silicone hydrogel contact lenses have received approval from the National Medical Products Administration in China.

The U.S. Food and Drug Administration has issued warning letters to three companies for marketing adulterated and misbranded COVID-19 antibody tests.